Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Chem Lab Med ; 45(9): 1224-8, 2007.
Article in English | MEDLINE | ID: mdl-17635079

ABSTRACT

BACKGROUND: As a component of the enzyme glutathione peroxidase, the essential trace element selenium contributes to the reduction of peroxides. Disturbed selenium availability may relate to an activated immune response. In humans, immune activation is reflected by increased neopterin production and accelerated tryptophan degradation, expressed as the kynurenine to tryptophan ratio (kyn/trp). Th1-type cytokine interferon-gamma induces both these immunobiological events in human macrophages and they are often activated in patients with cardiac disorders. The aim of this study was to determine the relationship between serum selenium concentrations and neopterin production and tryptophan degradation in patients with cardiac disorders. METHODS: In 56 patients (28 females) with cardiac disorders, serum selenium concentrations were determined by graphite-furnace atomic absorption spectrometry. Serum neopterin concentration was measured by ELISA and tryptophan degradation was examined by HPLC. RESULTS: Selenium concentrations were in the range 0.41-1.90 micromol/L (median 1.02) and were well within the local normal range. Approximately two-thirds of patients presented with higher neopterin concentrations (median 16.4 nmol/L) and tryptophan degradation (median 57 micromol/mmol kyn/trp). There was an inverse correlation between serum selenium and kyn/trp (Spearman's rank correlation, r(s)=-0.431; p<0.001) and neopterin concentrations (r(s)=-0.300; p<0.05). Neopterin concentrations correlated strongly with kyn/trp (r(s)=0.712; p<0.0001). CONCLUSIONS: A higher degree of tryptophan degradation and of neopterin production in patients with cardiac disorders coincides with lower, albeit still normal, serum selenium concentrations. Data show that in these patients immune activation is associated with lower serum selenium concentrations.


Subject(s)
Heart Diseases/blood , Immune System , Neopterin/metabolism , Selenium/blood , Selenium/metabolism , Aged , Chromatography, High Pressure Liquid , Enzyme-Linked Immunosorbent Assay , Female , Heart Diseases/metabolism , Humans , Male , Middle Aged , Models, Statistical , Oxidative Stress , Reproducibility of Results , Selenium/pharmacology , Tryptophan/chemistry
2.
High Alt Med Biol ; 6(2): 167-77, 2005.
Article in English | MEDLINE | ID: mdl-16060851

ABSTRACT

Moderate altitude hypoxia (1500 to 2500 m) is known to stimulate erythropoiesis and to improve oxygen transport to tissue by a reduction of Hb-O(2) affinity. Whether this adaptation also occurs in tourists with metabolic syndrome has not yet been investigated sufficiently. Thus, we performed a prospective field study to measure erythropoietic parameters and oxygen transport properties in 24 male volunteers with metabolic syndrome during a 3- week holiday program at 1700 m consisting of four guided, individually adapted hiking tours per week. The following examinations were performed: baseline investigations at 500 m (T1); examinations at moderate altitude on day 1 (T2), day 4 (T3), day 9 (T4), and day 19 (T5); and postaltitude tests (T6) 7 to 10 days after return. On day 1 and day 19, a walk on a standardized hiking test route with oxygen saturation (SpO(2)) measure points was performed. Hemoglobin, packed cell volume, and red cell count showed changes over time, with higher values at T5 as compared to baseline. Reticulocyte count and erythropoietin (EPO) were increased at T2 and increased further until T5. EPO declined toward prealtitude values. P50-value (blood PO(2) at 50% hemoglobin oxygen saturation at actual pH) increased during the altitude sojourn (maximum increase at T5 by +0.40 kPa). At T5 all volunteers had a higher SpO(2) before, during, and at the end of the test route compared to T1. During adaptation to moderate altitude, persons with metabolic syndrome exhibit an increase in EPO and a rightward shift of the oxygen dissociation curve that is similar to healthy subjects.


Subject(s)
Altitude , Erythropoiesis , Hemoglobins/metabolism , Metabolic Syndrome/blood , Oxygen Consumption , Acclimatization , Analysis of Variance , Austria , Erythropoietin , Follow-Up Studies , Humans , Male , Metabolic Syndrome/metabolism , Middle Aged , Prospective Studies , Reticulocyte Count , Time Factors
3.
J Mol Med (Berl) ; 82(6): 373-82, 2004 Jun.
Article in English | MEDLINE | ID: mdl-15173932

ABSTRACT

HFE affects the interaction of transferrin bound iron with transferrin receptors (TfR) thereby modulating iron uptake. To study genetically determined differences in HFE expression we examined individual HFE levels in C57BL/Sv129 mice and assessed their relationship to the regulation of iron homeostasis in the duodenum and the liver, and their regulation by diet. We found an up to 14-fold variation in inter-individual expression of HFE mRNA in the duodenum. Mice with high duodenal HFE mRNA expression presented with significantly higher levels of TfR and DMT-1 mRNAs and an increased IRP-1 binding affinity as compared to mice with low HFE levels. Duodenal HFE expression was positively associated with serum iron and liver HFE levels. Dietary iron supplementation decreased HFE in the duodenum but not in the liver. This was paralleled by reduced amounts of DMT-1 and FP-1 in the duodenum while the expression of DMT-1, FP-1, and hepcidin in the liver were increased with dietary iron overload. Duodenal and liver HFE levels are regulated by divergent penetration of as yet unelucidated modifier genes and to a much lesser extent by dietary iron. These measures control duodenal iron transport and liver iron homeostasis by modulating HFE expression either directly or via stimulation of iron sensitive regulatory molecules, such as hepcidin, which then exert their effects on body iron homeostasis.


Subject(s)
Antimicrobial Cationic Peptides/metabolism , Duodenum/metabolism , Histocompatibility Antigens Class I/metabolism , Iron-Regulatory Proteins/metabolism , Iron/metabolism , Membrane Proteins/metabolism , Animals , Antimicrobial Cationic Peptides/analysis , Antimicrobial Cationic Peptides/genetics , Gene Expression Regulation/drug effects , Genetic Variation , Hemochromatosis Protein , Hepcidins , Histocompatibility Antigens Class I/biosynthesis , Histocompatibility Antigens Class I/genetics , Homeostasis/genetics , Iron/blood , Iron, Dietary/pharmacology , Liver/chemistry , Liver/metabolism , Male , Membrane Proteins/biosynthesis , Membrane Proteins/genetics , Mice , RNA, Messenger/analysis
4.
Prostate ; 59(4): 401-8, 2004 Jun 01.
Article in English | MEDLINE | ID: mdl-15065088

ABSTRACT

BACKGROUND: Intermittent androgen ablation is a palliative treatment option for advanced prostate cancer which is associated with less side effects, improved quality of life of patients, and reduced costs. Regulation of growth and survival of prostate cancer cells during intermittent androgen withdrawal has not been studied in appropriate models yet. METHODS: Two cycles of androgen withdrawal and supplementation were performed in human prostate cancer cells LNCaP in vitro. Proliferation of prostate cancer cell sublines established after intermittent androgen withdrawal was assessed in the absence or presence of epidermal growth factor (EGF) by protein determination. Cell cycle was analyzed with a flow cytometer. EGF was measured in the supernatants of LNCaP sublines with a commercial ELISA. EGF receptor mRNA and protein were determined by real-time PCR and Western blot, respectively. RESULTS: Basal proliferation rate of all newly generated LNCaP sublines increased over that of the parental LNCaP cell line. The highest stimulation of proliferation by exogenous EGF was observed in parental LNCaP cells. In each LNCaP derivative established during intermittent androgen withdrawal, the percentage of cells in the S phase of cell cycle was higher than that in parental LNCaP cells. EGF levels did not increase during intermittent androgen ablation. The expression of EGF receptor protein decreased following each cycle of androgen ablation and increased subsequently after androgen supplementation. EGF receptor (EGFR) mRNA was regulated in a similar manner in LNCaP derivatives established during the second cycle of intermittent withdrawal. CONCLUSIONS: Changes in the expression of the EGF receptor occur during intermittent androgen ablation but they cannot be solely responsible for increased basal proliferation. Alternatively, other ligands and receptors of the EGF system may become overexpressed during prolonged withdrawal and supplementation of androgenic hormones in prostate cancer therapy.


Subject(s)
Androgen Antagonists/pharmacology , Androgen Antagonists/therapeutic use , Cell Cycle , Cell Division , ErbB Receptors/biosynthesis , Gene Expression Regulation, Neoplastic/drug effects , Prostatic Neoplasms/pathology , Blotting, Western , Enzyme-Linked Immunosorbent Assay , Flow Cytometry , Humans , Male , RNA, Messenger/analysis , Tumor Cells, Cultured
5.
Clin Chim Acta ; 331(1-2): 19-23, 2003 May.
Article in English | MEDLINE | ID: mdl-12691859

ABSTRACT

BACKGROUND: Determination of plasma homocysteine has gained increasing interest during the past few years. Several HPLC methods for determination of homocysteine are available. Based on these methods, we developed a new HPLC assay for rapid and sensitive measurement of total plasma homocysteine. METHODS: As a reducing reagent tris-(2-carboxylethyl)-phosphine is used, ammonium 7-fluorobenzo-2-oxa-1,3-diazole-4-sulfonate serves as the derivatization agent. Separation is performed by reversed-phase HPLC using a precolumn and a 55-mm RP(18) cartridge; mobile phase: 0.1 mol/l KH(2)PO(4) with 5% methanol, adjusted to pH 2.7 with ortho-phosphoric acid, flow-rate 1.1 ml/min. RESULTS: Homocysteine is clearly separated from other thiols, the retention time being 2.2 min, total analysis time is 6 min. Tests for linearity, recovery and precision are satisfactory, as well as the comparison with a commercial available assay method. Detection limit of the method is 0.5 micro mol/l, it could be further enhanced for measurements of even lower homocysteine concentrations in, e.g., cell culture supernatants. CONCLUSIONS: The described method is well suited for analysis of thiols in blood specimens. It is more convenient and more rapid than methods described earlier.


Subject(s)
Chromatography, High Pressure Liquid/methods , Homocysteine/blood , Humans , Indicators and Reagents , Oxidation-Reduction , Phosphines , Reproducibility of Results , Sensitivity and Specificity , Sulfhydryl Compounds/blood
6.
FEBS Lett ; 511(1-3): 123-6, 2002 Jan 30.
Article in English | MEDLINE | ID: mdl-11821061

ABSTRACT

Monocyte-derived dendritic cells (moDCs) are increasingly used in clinical settings to stimulate tumor immunity. Prostaglandin E2 (PGE2), which is a member of the eicosanoid family of oxygenated arachidonic acid derivatives generated through the action of cyclooxygenases (COXs), is frequently used to enhance the tumor necrosis factor-alpha-induced terminal maturation of moDCs. We show here that one effect of interleukin (IL)-4, which is used together with GM-CSF to generate moDCs, is the suppression of endogenous PGE2 production in moDCs. IL-4 inhibits the cytoplasmic form of phospholipase A2, the enzyme that specifically liberates arachidonic acid from membrane phospholipids. Although moDCs failed to mobilize endogenous arachidonic acid, they converted exogenous arachidonic acid into PGE2 in a COX-1- and COX-2-dependent fashion. IL-4-mediated suppression of PGE2 biosynthesis in human moDCs explains the previously reported maturation-enhancing effect of exogenous PGE2. The general suppression of eicosanoid biosynthesis may, however, limit the immunological efficacy of moDCs generated with IL-4.


Subject(s)
Cell Lineage , Dendritic Cells/cytology , Dendritic Cells/metabolism , Dinoprostone/biosynthesis , Dinoprostone/deficiency , Monocytes/cytology , Arachidonic Acid/metabolism , Arachidonic Acid/pharmacology , Blotting, Western , Cell Differentiation/drug effects , Cell Lineage/drug effects , Cells, Cultured , Dendritic Cells/drug effects , Dendritic Cells/enzymology , Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology , Humans , Interleukin-4/pharmacology , Lipopolysaccharides/pharmacology , Monocytes/drug effects , Phospholipases A/metabolism , Phospholipases A2
SELECTION OF CITATIONS
SEARCH DETAIL
...